Different sensitivities of the murine melanomas BL-6 and BL-6-beta m to local injections of interleukin-2 (IL-2). Analysis of gangliosides after the treatment.
The murine melanoma cell line BL-6-beta m, which is a stable cell line transfected with a gene coding a unique actin subspecies called beta m to the BL-6 cell line, has low metastatic potentials as compared with those of the parent cell line. BL-6-beta m melanomas were found to be sensitive to in vivo local injection of IL-2, while BL-6 melanomas showed almost no response. Ganglioside analysis of BL-6 and BL-6-beta melanomas revealed that the main ganglioside of both melanomas was GM3, which suggested that different sensitivities between BL-6 and BL-6-beta m melanomas to the injection of IL-2 did not relate to the different compositions of main gangliosides. However, minor components of the gangliosides such as GM2 and GM1 emerged only in BL-6-beta m melanomas after treatment with IL-2. Local injection of IL-2 caused considerable infiltration of anti-asialo GM1-positive cells into the nests as well as the interstitials of BL-6-beta m melanomas. In contrast, in the BL-6 melanomas treated with IL-2, infiltration of the anti-asialo GM1-positive cells was hardly seen, although anti-Thy1,2 and anti-macrophage-positive cells were found to more or less the same extent as observed in BL-6-beta m melanomas. These results suggest that the murine metastatic variant melanoma cell lines BL-6 and BL-6-beta m have different properties in terms of sensitivity to in vivo IL-2 treatment, and a slight enhancement of the ganglioside components GM2 and GM1 expression only in BL-6-beta m after IL-2 treatment may play a role in the IL-2-mediated attraction of immune cells or may explain the different sensitivities of the two lines to treatment with IL-2.
Department of Dermatology, Kyushu University Faculty of Medicine, Fukuoka, Japan.
J
J
Nakayama
T
T
Tsuchida
K
K
Toyofuku
R
R
Shimokawa-Kuroki
S
S
Taniguchi
Y
Y
Hori
D000199:Actins / Q000235:genetics / Q000502:physiology*; D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis; D002465:Cell Movement; D005260:Female; D005677:G(M1) Ganglioside / Q000032:analysis; D005732:Gangliosides / Q000032:analysis*; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007157:Immunologic Surveillance; D015552:Injections, Intralesional; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008546:Melanoma, Experimental / Q000737:chemistry / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D011993:Recombinant Fusion Proteins; D018800:Thy-1 Antigens / Q000032:analysis; D014162:Transfection
D000199:Actins; D000951:Antigens, Neoplasm; D005732:Gangliosides; D007155:Immunologic Factors; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; D018800:Thy-1 Antigens; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside